Prescription Options When IBS-C Constipation Won't Budge

What can actually be prescribed for IBS-C?

Secretagogues — that is the answer, and it is a short one. The ACG's IBS guideline recommends treatment by subtype, and for IBS with constipation the agents it points to are the secretagogues 1Ref 1Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That IBS is treated by subtype, that secretagogues are the recommended pharmacologic class for IBS with constipation, and that psychological therapies sit alongside drug therapy in the guideline's structure.. The NIDDK names IBS with constipation as one of the recognized IBS types, alongside diarrhea-predominant and mixed patterns 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017).Symptoms & Causes of Irritable Bowel Syndrome.That IBS with constipation is one of the recognized IBS types, alongside IBS with diarrhea and a mixed pattern.. Which subtype you are is therefore not a label. It is the thing that decides what can be written.

A secretagogue is an agent that makes the bowel secrete fluid. More fluid in the bowel means softer stool and easier passage — the name describes the mechanism rather than the brand.

This is the part worth internalizing before an appointment: IBS pharmacotherapy by subtype is not a marketing frame, it is how the guideline is organized. The drugs for IBS-D and the drugs for IBS-C are different drugs addressing opposite problems, which is why a clinician will not prescribe from this page's menu until they are satisfied the constipation subtype is the right one. If your pattern is genuinely mixed, the conversation is harder, and it is honest to say so rather than to pretend the menu resolves it.

There is more than one agent in the secretagogue class. Which one a clinician reaches for depends on your history, what you have already tried, and what your coverage will pay for — a decision that belongs in the room rather than on a page.

Why the constipation guideline isn't the IBS-C guideline

Because they are two documents about two conditions, and the difference is not academic. The joint AGA/ACG guideline on chronic idiopathic constipation covers fiber and polyethylene glycol, and makes strong recommendations for agents including linaclotide and lubiprostone 3Ref 3Chang L, Chey WD, Imdad A, et al. (2023).American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.That the joint AGA/ACG guideline for chronic idiopathic constipation covers fiber and polyethylene glycol and makes strong recommendations for agents including linaclotide and lubiprostone — in chronic idiopathic constipation specifically, a separate condition from IBS-C.. The ACG's IBS guideline covers IBS, where the recommendation for the constipation subtype is the secretagogue class 1Ref 1Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That IBS is treated by subtype, that secretagogues are the recommended pharmacologic class for IBS with constipation, and that psychological therapies sit alongside drug therapy in the guideline's structure.. The drug classes overlap. The evidence bases are filed separately, and so are the diagnoses.

A drug with strong evidence in chronic idiopathic constipation is not automatically a drug with the same evidence in IBS-C. Overlapping classes, separate guidelines, separate trials.

This is the distinction that most IBS-C drug lists quietly collapse. They print a menu of agents, attach the phrase strongly recommended, and never mention that the strength of that recommendation was measured in a population defined by constipation without the pain criterion. The drugs may well be the right ones. The evidence sentence attached to them is just not as clean as the list implies.

Why it matters to you rather than to a committee: it explains why a clinician might be more confident about what a drug does to your stool than about what it does to your pain, and why the answer to "will this fix it" is often narrower than you hoped.

Pain is the hinge

What separates IBS with constipation from chronic constipation on its own is abdominal pain. The NIDDK defines constipation itself as a symptom rather than a disease — fewer than three bowel movements a week, or stools that are hard, dry, lumpy, difficult, or incompletely passed 4Ref 4National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2018).Definition & Facts for Constipation.The clinical definition of constipation — fewer than three bowel movements per week, or hard, dry, lumpy, difficult, or incompletely passed stools — and that constipation is a symptom rather than a disease.. Nothing in that definition mentions pain. The Rome IV revision made pain the center of the IBS criteria, specifically abdominal pain related to defecation 5Ref 5Schmulson MJ, Drossman DA (2017).What Is New in Rome IV.That the Rome IV revision centers the IBS criteria on abdominal pain related to defecation, rather than on 'discomfort'..

Constipation is defined as fewer than three bowel movements a week, or stools that are hard, dry, lumpy, difficult, or incompletely passed 4Ref 4National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2018).Definition & Facts for Constipation.The clinical definition of constipation — fewer than three bowel movements per week, or hard, dry, lumpy, difficult, or incompletely passed stools — and that constipation is a symptom rather than a disease.. Pain is not part of that definition.

So the IBS-C definition is constipation plus pain that relates to your bowel movements — pain that changes when you go, or arrives with the change in habit. That is what makes a person's constipation an IBS question rather than a plumbing question, and it is why the two guidelines exist in parallel.

In practice, the hinge shows up in what you get asked. A clinician working out whether to reach for the IBS shelf or the constipation shelf will ask about pain and its relationship to defecation, not just about frequency. Answering that precisely — the cramping eases after I go or it doesn't change at all — does more to steer the prescription than any description of how long it has been going on.

What gets tried before a prescription

Fiber and an osmotic laxative, in most cases. The joint AGA/ACG constipation guideline addresses fiber and polyethylene glycol alongside the prescription agents 3Ref 3Chang L, Chey WD, Imdad A, et al. (2023).American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.That the joint AGA/ACG guideline for chronic idiopathic constipation covers fiber and polyethylene glycol and makes strong recommendations for agents including linaclotide and lubiprostone — in chronic idiopathic constipation specifically, a separate condition from IBS-C., and in practice these are what a clinician works through before the conversation turns to something written. This is not a hurdle placed in your way. It is that the inexpensive, well-understood options resolve the problem for a meaningful number of people, and finding out costs weeks rather than months.

What makes this step fail more often than it should is that it gets done badly:

• Fiber given a week instead of a trial. A few days is not an answer, and stopping early leaves everyone in the room guessing.
• An osmotic taken occasionally. Used as a rescue on the worst days, it is being asked to do a job it was not designed for.
• Both at once, started together. When two things change on the same day and something improves, nothing has been learned about which one did it.

The purpose of doing this properly is not obedience. It is that a clinician who can see a clean, documented failure of fiber and an osmotic has a much easier time justifying the next step — to themselves and, when the prior authorization arrives, to your insurer.

What a secretagogue does not do

It does not cure IBS, and it does not necessarily touch the pain. The IBS guideline's structure makes this fairly explicit: it treats the subtypes separately and places psychological therapies alongside the drug options rather than after them 1Ref 1Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That IBS is treated by subtype, that secretagogues are the recommended pharmacologic class for IBS with constipation, and that psychological therapies sit alongside drug therapy in the guideline's structure. — a design that only makes sense if the drug is not expected to carry the whole condition. Moving stool and relieving abdominal pain are two jobs, and one prescription is not automatically both.

The realistic goal is a bowel habit you can live with, not a bowel habit you stop noticing.

This is worth saying because of what happens when the expectation is wrong. A person starts a secretagogue, the constipation improves, the pain does not, and they conclude the drug failed and IBS is untreatable. What actually happened is that one of two problems got addressed. The other one has its own menu — dietary work, brain-gut therapies, and in some cases medications aimed at pain rather than at transit.

The mirror-image situation is worth knowing too. Prescription drugs for IBS-D are a separate menu for the opposite subtype, and people whose pattern shifts over the years sometimes move between them.

What to bring to the appointment

A record of what you have already tried, and for how long. The prescription conversation for IBS-C moves faster when a clinician can see that fiber was given a real trial rather than a week, that an osmotic was used consistently rather than occasionally, and what each one actually did. Without that, the first visit tends to end with a recommendation to go and try them properly.

Worth writing down beforehand:

• Frequency and form, over a typical two weeks rather than your worst week.
• Whether pain relates to defecation — does it ease after you go, worsen, or stay flat?
• Every OTC product tried, with how long each ran and at what consistency.
• What you have cut from your diet, and whether cutting it changed anything measurable.

One question that deserves a straight answer: people with stubborn constipation often ask which colonoscopy prep options are gentler, because a prep on top of an already stuck bowel is a daunting prospect. It is a fair question, and a separate one — it belongs to whoever is ordering the procedure rather than to the IBS-C prescription decision.

When constipation isn't the story

Some constipation is not a motility problem to be medicated. The NIDDK lists the signs that call for prompt evaluation rather than a prescription: rectal bleeding, blood in the stool, constant abdominal pain, an inability to pass gas, vomiting, and unintentional weight loss — along with a family history of colorectal cancer 6Ref 6National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2018).Symptoms & Causes of Constipation.The constipation warning signs prompting prompt medical evaluation: rectal bleeding, blood in stool, constant abdominal pain, inability to pass gas, vomiting, unintentional weight loss, and a family history of colorectal cancer.. These are not a longer version of the same problem. They are a different question.

None of these is cancelled by having IBS-C. A person with a years-old IBS-C diagnosis who starts passing blood does not have a complicated case of IBS-C; they have bleeding that needs looking at, and the existing diagnosis is precisely what makes it likely to be dismissed. Whether it is IBS or colon cancer is not a question to answer by reasoning from which is more common. It is answered by being seen — within days for visible blood, and immediately for an inability to pass gas or stool combined with vomiting, which is a bowel-obstruction presentation and belongs in an emergency department.

A new family history counts too. If a first-degree relative is diagnosed with colorectal cancer, the screening conversation changes regardless of how well your constipation is being managed, and it is worth raising at the next appointment rather than the next screening birthday.